Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,556 | -10,176 | -7,408 | -3,679 | -1,946 |
| Depreciation Amortization | 7 | 7 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -1,664 | 1,816 | -894 | -314 | -742 |
| Other Working Capital | 37 | 1,812 | 722 | -1,042 | 183 |
| Other Operating Activity | 1,675 | -1,264 | 1,299 | 621 | 797 |
| Operating Cash Flow | $-3,501 | $-7,806 | $-6,281 | $-4,414 | $-1,707 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -124 | N/A | N/A | N/A |
| Purchase Of Investment | N/A | N/A | -124 | N/A | N/A |
| Investing Cash Flow | $N/A | $-124 | $-124 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 5,872 | 5,188 | 3,691 | 1,448 |
| Other Financing Activity | -64 | 2,866 | -613 | -567 | -190 |
| Financing Cash Flow | $-64 | $8,738 | $4,575 | $3,124 | $1,258 |
| Beginning Cash Position | 4,310 | 3,502 | 3,502 | 3,502 | 3,502 |
| End Cash Position | 746 | 4,310 | 1,673 | 2,212 | 3,053 |
| Net Cash Flow | $-3,565 | $808 | $-1,829 | $-1,291 | $-450 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,501 | -7,806 | -6,281 | -4,414 | -1,707 |
| Capital Expenditure | N/A | -124 | N/A | N/A | N/A |
| Free Cash Flow | -3,501 | -7,930 | -6,281 | -4,414 | -1,707 |